Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
August 2006
Features
Health Care and Law
The FDA’s First Moves to Supplant Randomized Controlled Clinical Trials
Is the traditional randomized controlled trial on the way out? Efforts are under way to promote a new trial design, known as the adaptive trial.
Robert I. Field, JD, MPH, PhD
Meeting Highlights
American Diabetes Association
A regimen of insulin glargine (Lantus) and insulin glulisine (Apridra) is compared with carbohydrate counting to lower glycosylated hemoglobin levels; colesevelam (Welchol), a lipid-lowering agent, benefits glycemic control; and an oral agent, vildagliptin (Galvus), targets pancreatic islet dysfunction.
Reuben B. David
Meeting Highlights
Multiple Sclerosis Symposium and American Society of Hypertension
Aliskiren (Rasilez) in combination with hydrochlorothiazide is beneficial for uninterrupted blood pressure control over 24 hours, and valsartan (Diovan) is used for reducing high-sensitivity C-reactive protein levels.
Walter Alexander
Continuing Education Credit
An Overview of Overactive Bladder and Its Pharmacological Management with a Focus on Anticholinergic Drugs
Older and newer agents, as well as nonpharmacological options, are reviewed along with a discussion of urinary incontinence, bladder physiology, and patient education.
George DeMaagd, PharmD, BCPS, and Jeffrey D. Geibig, PharmD
Departments
Editorial
Foot Soldiers for EBM
David Nash, MD, MBA, discusses an experimental concept in which an “unsales” force would use evidence-based tools in an effort to encourage doctors to focus on lowering drug costs in Pennsylvania (e.g., by prescribing generic drugs).
David Nash, MD, MBA
Prescription: Washington
Pressure Builds to Untie the FDA’s Hands on Generics: High Drug Prices Still Fuel Public–Hence Political–Pressure
Stephen Barlas comments on the pressure to increase the
number of generic versions of brand-name drugs and one of the constraints facing the FDA, namely Citizen Petitions.
Stephen Barlas
Medication Errors
Water, Water, Everywhere, but Please Don’t Give IV
Matthew Grissinger, RPh, FASCP, examines the inappropriate use of IV sterile water.
Matthew Grissinger, RPh, FASCP
New Drugs/Drug News/New Medical Devices
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Drospirenone/Estradiol (Angeliq) for the Treatment of Menopausal Symptoms
The authors review a drospirenone/estradiol combination (Angeliq) to treat menopausal symptoms.
Nasya Ezell, PharmD Candidate, Alicia Hardy, PharmD Candidate, Marlon Honeywell, PharmD, Angela Singh, PharmD, Jessica Warthen, PharmD, and Patty Ghazvini, PharmD
